Jack Anthony
Mr. Anthony most recently was chief executive officer at Pharmix Corp., a San Francisco-based computational design drug company. Prior to Pharmix, Mr. Anthony was responsible for creating many successful in-licensing and out- licensing partnerships, as senior vice president of business development at Saegis Pharmaceuticals, now part of Lundbeck of Denmark. Mr. Anthony also was senior vice president of business development at Tularik, where he played an instrumental role in the acquisition of Tularik by Amgen in 2004. Mr. Anthony has served in senior business development and marketing positions at such innovative biotechnology firms as FibroGen, Cell Therapeutics, and Inhale (now Nektar) Therapeutics, negotiating research, development and commercialization deals with numerous universities, and global biotechnology and pharmaceutical companies. Mr. Anthony began his career in life sciences with Baxter Healthcare Corporation, where he spent more than 15 years, ultimately serving as a vice president of Baxter's Blood Therapy Group. He earned a Bachelor of Science degree in biology from Allegheny College.

Bruce Jenett
Mr. Jenett's practice is focused on the representation of domestic and international business and finance clients in the life sciences industry. He served for seven years as co-chairman of Heller Ehrman’s life sciences practice. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Mr. Jenett has, for example, represented clients in the largest (in financial terms) ag-bio partnering deal done to date, and the largest (also in financial terms) partnering deal done to date by an Irish venture capital-backed biotechnology company with a major pharmaceutical company. Mr. Jenett has represented such clients as Abingworth Management, Inc., Astellas Venture Capital LLC, Bayer Corporation and Bayer AG, CardioGenesis Corporation, Entelos, Inc., Exelixis, Inc., Hitachi Chemical Diagnostics, Nautilus Biotech S.A., OptiMedica Corporation, Pelikan Technologies, Inc., Presidio Pharmaceuticals, Inc., Thoratec Corporation, Trellis Bioscience, Inc., TPG Ventures, VisionCare Ophthalmic Technologies, Inc., and numerous life sciences and telecommunications start-up incubators. Mr. Jenett is a frequent speaker on corporate and finance issues to both business and attorney audiences. He is a member of the Bioethics Committee of BIO, of the Advisory Board of BioAgenda, and of the BayBio Board of Directors, and is a member of, and is Co-Chair of the Strategic Planning Committee of, San Francisco Mayor Gavin Newsom's Biotech Advisory Council. Mr. Jenett also is named consistently as one of the leading business lawyers in the United States by Chambers & Partners, and as a leading biotechnology industry lawyer in "Best Lawyers In America" for 2007 and 2008, and is on the Law & Politics "Super Lawyers" list for Northern California for corporate and securities law for 2007 and 2008.

Thomas B. King
Thomas B. King has served as Alexza Pharmaceuticals President, Chief Executive Officer and a member of Alexza Pharmaceuticals board of directors since June 2003. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From December 1994 to February 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors at Anesta Corporation, a publicly traded pharmaceutical company, until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College.

Steven James
Mr. James joined KAI as President and CEO in October 2004. He has nearly twenty years of pharmaceutical, biotechnology and start-up experience in the life science industry. Mr. James began his career in new product planning at Eli Lilly followed by California Biotechnology (Scios/J&J). In 1990 he joined Landec Corporation, a specialty materials company, as Vice President of Business Development and General Manager. During his 7 years at Landec Mr. James led commercial strategy, product launches and negotiated diverse alliances with Hitachi Chemical, Ciba Geigy, Smith & Nephew among others, leading to an IPO in 1995. Mr. James then returned to biotech as Vice President of Business Development at Isis, where he was instrumental in establishing business units in functional genomics and small molecule discovery and negotiating partnerships with Merck, Zeneca, and Abbott. In 1999 Mr. James joined Sunesis as Senior Vice President and member of the board of directors, and later, Chief Business Officer. At Sunesis he played a key role in raising over $80 million of venture and partner financing and securing alliances with Merck, J&J, and Biogen. Most recently, Mr. James was Senior Vice President of Commercial Operations at Exelixis. Mr. James has a biology degree from Brown University and a Masters in Management from the Kellogg School of Northwestern University.

Gail Maderis
Gail Maderis brings over 20 years of management experience in healthcare to her position as President and CEO at FivePrime Therapeutics. Prior to joining FivePrime, she held various business development and general management positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology, a publicly traded division of Genzyme, and corporate vice president of Genzyme Corporation. Previously, Ms. Maderis practiced management and strategy consulting with Bain & Co., Inc. Ms. Maderis currently serves as a board member with BayBio and is a member of the Mayor's Biotech Advisory Council of San Francisco. She received a B.S. degree in business from the University of California at Berkeley and an M.B.A. from Harvard Business School.

Arlene M. Morris
Ms. Morris has served as president and chief executive officer and a member of Affymax’s board of directors since 2003. From 2001 to 2003, Ms. Morris served as president and chief executive officer at Clearview Projects, an advisory firm to biopharmaceutical and biotechnology companies on strategic transactions. From 1996 to 2001, Ms. Morris served as senior vice president of Business Development at Coulter Pharmaceutical, Inc., a pharmaceutical company. From 1993 to 1996, Ms. Morris served as vice president of Business Development at Scios Inc., a biopharmaceutical company. From 1977 to 1993, Ms. Morris held positions of increasing responsibility at Johnson & Johnson, including vice president of Business Development for McNeil Pharmaceutical. Ms. Morris serves as a member of the board of directors of MediciNova, Inc., Phenomix Corp. and the Biotechnology Industry Organization. Ms. Morris holds a B.A. from Carlow College and has studied marketing at Western New England College.